Retatrutide
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials recorded up to 24.2% body weight reduction — the highest of any compound in its class.
Studied Benefits
- Triple-receptor agonism (GLP-1/GIP/glucagon)
- Appetite research in Phase 2 trials
- Body-weight reduction in TRIUMPH-1 data
- Metabolic-regulation research
Research Use Only
This compound is intended for laboratory and research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional.
Independently Reviewed
We only list vendors that provide third-party, batch-specific COAs.
Apollo Peptide Sciences
Buy Direct from Apollo Peptide Sciences →Ignite Peptides
Buy Direct from Ignite Peptides →Peak Lab Peptides
Buy Direct from Peak Lab Peptides →Main Peptides
Buy Direct from Main Peptides →Affiliate disclosure: links above are affiliate partnerships. We may earn a commission at no cost to you.
Related in Body Composition
Semaglutide (GLP-1)
GLP-1 receptor agonist widely studied for appetite regulation, blood sugar control, and body composition.
View product →
Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for synergistic effects on insulin secretion, fat metabolism, and appetite suppression — showing a greater magnitude of weight loss than semaglutide in head-to-head trials.
View product →
Make this protocol yours
The Engine reads your biometrics and personalizes dosing, timing, and stacking — free at engine.auraprotocols.com.
Try the Engine →